231 related articles for article (PubMed ID: 30408848)
1. Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.
Eichler H; Angchaisuksiri P; Kavakli K; Knoebl P; Windyga J; Jiménez-Yuste V; Harder Delff P; Chowdary P
Haemophilia; 2019 Jan; 25(1):60-66. PubMed ID: 30408848
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.
Eichler H; Angchaisuksiri P; Kavakli K; Knoebl P; Windyga J; Jiménez-Yuste V; Hyseni A; Friedrich U; Chowdary P
J Thromb Haemost; 2018 Nov; 16(11):2184-2195. PubMed ID: 30137664
[TBL] [Abstract][Full Text] [Related]
3. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.
Waters EK; Sigh J; Friedrich U; Hilden I; Sørensen BB
Haemophilia; 2017 Sep; 23(5):769-776. PubMed ID: 28594458
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Chowdary P
Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
[TBL] [Abstract][Full Text] [Related]
5. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.
Yuan D; Rode F; Cao Y
Eur J Pharm Sci; 2019 Oct; 138():105032. PubMed ID: 31394258
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.
Shapiro AD; Angchaisuksiri P; Astermark J; Benson G; Castaman G; Chowdary P; Eichler H; Jiménez-Yuste V; Kavakli K; Matsushita T; Poulsen LH; Wheeler AP; Young G; Zupancic-Salek S; Oldenburg J
Blood; 2019 Nov; 134(22):1973-1982. PubMed ID: 31444162
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
Chowdary P; Lethagen S; Friedrich U; Brand B; Hay C; Abdul Karim F; Klamroth R; Knoebl P; Laffan M; Mahlangu J; Miesbach W; Dalsgaard Nielsen J; Martín-Salces M; Angchaisuksiri P
J Thromb Haemost; 2015 May; 13(5):743-54. PubMed ID: 25641556
[TBL] [Abstract][Full Text] [Related]
8. Concizumab: a novel anti-TFPI therapeutic for hemophilia.
Shapiro AD
Blood Adv; 2021 Jan; 5(1):279. PubMed ID: 33570646
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration.
Agersø H; Overgaard RV; Petersen MB; Hansen L; Hermit MB; Sørensen MH; Petersen LC; Hilden I
Eur J Pharm Sci; 2014 Jun; 56():65-9. PubMed ID: 24568891
[TBL] [Abstract][Full Text] [Related]
10. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor.
Hansen L; Petersen LC; Lauritzen B; Clausen JT; Grell SN; Agersø H; Sørensen BB; Hilden I; Almholt K
Thromb Res; 2014 Mar; 133(3):464-71. PubMed ID: 24393663
[TBL] [Abstract][Full Text] [Related]
11. Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody.
Crépin R; Morin C; Montmartin A; Tardy-Poncet B; Chelle P
J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):563-580. PubMed ID: 33846873
[TBL] [Abstract][Full Text] [Related]
12. Concizumab: First Approval.
Keam SJ
Drugs; 2023 Jul; 83(11):1053-1059. PubMed ID: 37341887
[TBL] [Abstract][Full Text] [Related]
13. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
[TBL] [Abstract][Full Text] [Related]
14. Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B.
Tardy-Poncet B; Montmartin A; Chambost H; Lienhart A; Frotscher B; Morange PE; Falaise C; Collange F; Dargaud Y; Toussaint-Hacquard M; Ardillon L; Wibaut B; Jeanpierre E; Nguyen P; Volot F; Tardy B
Haemophilia; 2024 May; 30(3):693-701. PubMed ID: 38650319
[TBL] [Abstract][Full Text] [Related]
15. Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic-pharmacodynamic model for patients with haemophilia A.
Bukkems LH; Valke LLFG; Barteling W; Laros-van Gorkom BAP; Blijlevens NMA; Cnossen MH; van Heerde WL; Schols SEM; Mathôt RAA
Br J Clin Pharmacol; 2022 Jun; 88(6):2757-2768. PubMed ID: 34921439
[TBL] [Abstract][Full Text] [Related]
16. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
[TBL] [Abstract][Full Text] [Related]
17. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia.
Mahlangu JN; Coetzee MJ; Laffan M; Windyga J; Yee TT; Schroeder J; Haaning J; Siegel JE; Lemm G
J Thromb Haemost; 2012 May; 10(5):773-80. PubMed ID: 22353395
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors.
Shapiro AD; Angchaisuksiri P; Astermark J; Benson G; Castaman G; Eichler H; Jiménez-Yuste V; Kavakli K; Matsushita T; Poulsen LH; Wheeler AP; Young G; Zupančić-Šalek S; Oldenburg J; Chowdary P
Blood Adv; 2022 Jun; 6(11):3422-3432. PubMed ID: 35290453
[TBL] [Abstract][Full Text] [Related]
19. Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents.
Mancuso ME; Chantarangkul V; Clerici M; Fasulo MR; Padovan L; Scalambrino E; Peyvandi F; Tripodi A; Santagostino E
Haemophilia; 2016 Jul; 22(4):e292-300. PubMed ID: 27197961
[TBL] [Abstract][Full Text] [Related]
20. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
Matsushita T; Shapiro A; Abraham A; Angchaisuksiri P; Castaman G; Cepo K; d'Oiron R; Frei-Jones M; Goh AS; Haaning J; Hald Jacobsen S; Mahlangu J; Mathias M; Nogami K; Skovgaard Rasmussen J; Stasyshyn O; Tran H; Vilchevska K; Villarreal Martinez L; Windyga J; You CW; Zozulya N; Zulfikar B; Jiménez-Yuste V;
N Engl J Med; 2023 Aug; 389(9):783-794. PubMed ID: 37646676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
